Nicotinic acid derivative (xanthinol nicotinate) induced bullous eruption

S.A. Khan, G. Rodrigues, P.G.M. Rao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. © 2006 - IOS Press and the authors. All rights reserved.
Original languageEnglish
Pages (from-to)159-162
Number of pages4
JournalInternational Journal of Risk and Safety in Medicine
Volume18
Issue number3
Publication statusPublished - 2006

Fingerprint

Xanthinol Niacinate
Niacin
Hyperlipidemias
Drug-Related Side Effects and Adverse Reactions
Blood Vessels

Cite this

@article{38e97b40dbc24dd59797fec922402e11,
title = "Nicotinic acid derivative (xanthinol nicotinate) induced bullous eruption",
abstract = "Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. {\circledC} 2006 - IOS Press and the authors. All rights reserved.",
author = "S.A. Khan and G. Rodrigues and P.G.M. Rao",
note = "Cited By :3 Export Date: 10 November 2017 CODEN: IJMDE Correspondence Address: Khan, S.A.; Faculty and Research Scholar, Dept. of Pharmacy Practice, S S Cancer Hospital and Research Centre, Manipal-576 104, Karnataka, India; email: sohailkhan1981@gmail.com Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; cilostazol, 73963-72-1; nicotinic acid, 54-86-4, 59-67-6; xanthinol nicotinate, 437-74-1 Tradenames: aspirin; complamina References: ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias (1997) Am. J. Health Syst. Pharm., 54, pp. 2815-2819; Davis, E., Rozov, H., Xanthinol nicotinate in peripheral vascular disease (1975) Practitioner, 215, pp. 793-798; Ganzer, B.M., Langzeitstudie zu acipimox (1990) Pharmazie, 135, p. 31; Goldberg, A.C., Clinical trial experience with extended-release niacin (Niaspan): Dose-escalation study (1998) Am. J. Cardiol., 82, pp. 35U-38U; Hartwig, S.C., Siegel, J., Schneider, P.J., Preventability and severity assessment in reporting adverse drug reactions (1992) Am. J. Hosp. Pharm., 49, pp. 2229-2232; Lehmann, E., Van Der Crone, L., Grobe-Einsler, R., Linden, M., Drug monitoring study (phase IV) of xantinol nicotinate (Complamin) in general practice (1993) Pharmacopsychiatry, 26, pp. 42-48; Luria, M.H., Atherosclerosis: The importance of HDL cholesterol and prostacyclin: A role for niacin therapy (1990) Med. Hypothesis, 31, pp. 21-28; Miller, S.M., Potential perils of niacin therapy (1991) Clin. Lab. Sci., 4, pp. 156-158; Morgan, J.M., Capuzzi, D.M., Guyton, J.R., A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients (1998) Am. J. Cardiol., 82, pp. 29-34; Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janecek, E., Greenblatt, D.J., A method for estimating the probability of adverse drug reaction (1981) Clin. Pharmacol. Therapeutics, 30, pp. 239-245; (1990) Facts and Comparisons, , B. Olin, ed., Facts and Comparison, Inc, St Louis, MO; Prosser, T.R., Kamysz, P.L., Multidisciplinary adverse drug reaction surveillance (1990) Am. J. Hosp. Pharm., 47, pp. 1334-1339; Verhaeghe, R., Drugs acting on the cerebral and peripheral circulations and drugs used in the treatment of migraine (2000) Meyler's Side Effects of Drugs, pp. 629-630. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam; Vrhovac, B., Drugs affecting lipid metabolism (2000) Meyler's Side Effects of Drugs, pp. 1527-1535. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam",
year = "2006",
language = "English",
volume = "18",
pages = "159--162",
journal = "International Journal of Risk and Safety in Medicine",
issn = "0924-6479",
publisher = "IOS Press",
number = "3",

}

Nicotinic acid derivative (xanthinol nicotinate) induced bullous eruption. / Khan, S.A.; Rodrigues, G.; Rao, P.G.M.

In: International Journal of Risk and Safety in Medicine, Vol. 18, No. 3, 2006, p. 159-162.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nicotinic acid derivative (xanthinol nicotinate) induced bullous eruption

AU - Khan, S.A.

AU - Rodrigues, G.

AU - Rao, P.G.M.

N1 - Cited By :3 Export Date: 10 November 2017 CODEN: IJMDE Correspondence Address: Khan, S.A.; Faculty and Research Scholar, Dept. of Pharmacy Practice, S S Cancer Hospital and Research Centre, Manipal-576 104, Karnataka, India; email: sohailkhan1981@gmail.com Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; cilostazol, 73963-72-1; nicotinic acid, 54-86-4, 59-67-6; xanthinol nicotinate, 437-74-1 Tradenames: aspirin; complamina References: ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias (1997) Am. J. Health Syst. Pharm., 54, pp. 2815-2819; Davis, E., Rozov, H., Xanthinol nicotinate in peripheral vascular disease (1975) Practitioner, 215, pp. 793-798; Ganzer, B.M., Langzeitstudie zu acipimox (1990) Pharmazie, 135, p. 31; Goldberg, A.C., Clinical trial experience with extended-release niacin (Niaspan): Dose-escalation study (1998) Am. J. Cardiol., 82, pp. 35U-38U; Hartwig, S.C., Siegel, J., Schneider, P.J., Preventability and severity assessment in reporting adverse drug reactions (1992) Am. J. Hosp. Pharm., 49, pp. 2229-2232; Lehmann, E., Van Der Crone, L., Grobe-Einsler, R., Linden, M., Drug monitoring study (phase IV) of xantinol nicotinate (Complamin) in general practice (1993) Pharmacopsychiatry, 26, pp. 42-48; Luria, M.H., Atherosclerosis: The importance of HDL cholesterol and prostacyclin: A role for niacin therapy (1990) Med. Hypothesis, 31, pp. 21-28; Miller, S.M., Potential perils of niacin therapy (1991) Clin. Lab. Sci., 4, pp. 156-158; Morgan, J.M., Capuzzi, D.M., Guyton, J.R., A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients (1998) Am. J. Cardiol., 82, pp. 29-34; Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janecek, E., Greenblatt, D.J., A method for estimating the probability of adverse drug reaction (1981) Clin. Pharmacol. Therapeutics, 30, pp. 239-245; (1990) Facts and Comparisons, , B. Olin, ed., Facts and Comparison, Inc, St Louis, MO; Prosser, T.R., Kamysz, P.L., Multidisciplinary adverse drug reaction surveillance (1990) Am. J. Hosp. Pharm., 47, pp. 1334-1339; Verhaeghe, R., Drugs acting on the cerebral and peripheral circulations and drugs used in the treatment of migraine (2000) Meyler's Side Effects of Drugs, pp. 629-630. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam; Vrhovac, B., Drugs affecting lipid metabolism (2000) Meyler's Side Effects of Drugs, pp. 1527-1535. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam

PY - 2006

Y1 - 2006

N2 - Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. © 2006 - IOS Press and the authors. All rights reserved.

AB - Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. © 2006 - IOS Press and the authors. All rights reserved.

M3 - Article

VL - 18

SP - 159

EP - 162

JO - International Journal of Risk and Safety in Medicine

JF - International Journal of Risk and Safety in Medicine

SN - 0924-6479

IS - 3

ER -